4.5 Article

Mexiletine Reverses Oxaliplatin-Induced Neuropathic Pain in Rats

期刊

JOURNAL OF PHARMACOLOGICAL SCIENCES
卷 112, 期 4, 页码 473-476

出版社

JAPANESE PHARMACOLOGICAL SOC
DOI: 10.1254/jphs.10012SC

关键词

mexiletine; oxaliplatin; neuropathic pain

资金

  1. Ministry of Education, Culture, Sports, Science, and Technology of Japan [21590285]
  2. Grants-in-Aid for Scientific Research [21590285] Funding Source: KAKEN

向作者/读者索取更多资源

Oxaliplatin is a platinum-based chemotherapy drug characterized by the development of acute and chronic peripheral neuropathies. Mexiletine, an orally available Na(+)-channel blocker, has widely been used in patients with chronic painful diabetic neuropathy. In the present study, we examined the effect of mexiletine on oxaliplatin-induced neuropathic pain in rats. Mexiletine (100, but not 10 and 30, mg/kg, p.o.) completely reversed both mechanical allodynia and cold hyperalgesia induced by oxaliplatin (4 mg/kg, i.p., twice a week). Lidocaine (30, but not 3 and 10, mg/kg, i.p.) also significantly relieved both pain behaviors. These results suggest that mexiletine may be effective in relieving the oxaliplatin-induced neuropathic pain clinically.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Infectious Diseases

Safety and efficacy evaluation of low-dose trimethoprim-sulfamethoxazole for prophylaxis of Pneumocystis pneumonia in HIV uninfected patients undergoing hemodialysis: a retrospective observational study

Kanae Yamashita, Yoshimitsu Shimomura, Hiroaki Ikesue, Nobuyuki Muroi, Akihiro Yoshimoto, Tohru Hashida

Summary: The study found that low-dose TMP-SMX is effective and safe for PCP prophylaxis in patients undergoing hemodialysis, with a significantly lower cumulative discontinuation rate due to adverse events compared to the standard-dose group.

BMC INFECTIOUS DISEASES (2021)

Article Multidisciplinary Sciences

Analysis of chemotherapy-induced peripheral neuropathy using the Japanese Adverse Drug Event Report database

Misaki Inoue, Kiyoka Matsumoto, Mizuki Tanaka, Yu Yoshida, Riko Satake, Fumiya Goto, Kazuyo Shimada, Ririka Mukai, Shiori Hasegawa, Takaaki Suzuki, Hiroaki Ikesue, Jun Liao, Tohru Hashida, Mitsuhiro Nakamura

Summary: Chemotherapy-induced peripheral neuropathy (CIPN) is a common adverse event associated with several anticancer drugs. Analysis of the Japanese Adverse Drug Event Report (JADER) database revealed that certain drugs, such as vinca alkaloids, taxanes, platinum compounds, and monoclonal antibodies, have a high risk for CIPN development, with varying time-to-onset and outcomes. CIPN caused by nab-paclitaxel shows a faster onset compared to sb-paclitaxel, and early treatment may be necessary for patients who receive taxanes or monoclonal antibodies and do not show improvement.

SCIENTIFIC REPORTS (2021)

Article Pharmacology & Pharmacy

Analysis of Drug-Induced Gastrointestinal Obstruction and Perforation Using the Japanese Adverse Drug Event Report Database

Riko Satake, Kiyoka Matsumoto, Mizuki Tanaka, Ririka Mukai, Kazuyo Shimada, Yu Yoshida, Misaki Inoue, Shiori Hasegawa, Kazuhiro Iguchi, Hiroaki Ikesue, Shinya Shimizu, Shohei Nishida, Akio Suzuki, Tohru Hashida, Mitsuhiro Nakamura

Summary: Drug-induced gastrointestinal obstruction and perforation can result in life-threatening complications. Different drug categories have varying onset times for adverse events, highlighting the importance of detailed monitoring to prevent fatal consequences.

FRONTIERS IN PHARMACOLOGY (2021)

Article Immunology

Pharmacodynamic Evaluation of Ampicillin-sulbactam in Pediatric Patients Using Plasma and Urine Data

Tetsushu Onita, Kazuro Ikawa, Noriyuki Ishihara, Hiroki Tamaki, Takahisa Yano, Kohji Naora, Norifumi Morikawa

Summary: PK models of ampicillin and sulbactam were developed, and the recommended dosage for empirical therapy of community-acquired pneumonia is 75mg/kg q.i.d.

PEDIATRIC INFECTIOUS DISEASE JOURNAL (2022)

Article Oncology

Risk evaluation of denosumab and zoledronic acid for medication-related osteonecrosis of the jaw in patients with bone metastases: a propensity score-matched analysis

Hiroaki Ikesue, Kohei Doi, Mayu Morimoto, Masaki Hirabatake, Nobuyuki Muroi, Shinsuke Yamamoto, Toshihiko Takenobu, Tohru Hashida

Summary: This study found that patients treated with denosumab for bone metastasis have a higher risk of developing medication-related osteonecrosis of the jaw (MRONJ) compared to those treated with zoledronic acid, highlighting the need for close monitoring for patients on denosumab.

SUPPORTIVE CARE IN CANCER (2022)

Article Oncology

Risk factors of proteinuria and potentially protective effect of renin-angiotensin system inhibitors in patients with renal cell carcinoma receiving axitinib

Hiroaki Ikesue, Kenta Yamaoka, Ayako Matsumoto, Masaki Hirabatake, Nobuyuki Muroi, Toshinari Yamasaki, Mutsushi Kawakita, Tohru Hashida

Summary: This study investigated the risk factors for proteinuria and the protective effect of renin-angiotensin system (RAS) inhibitors in patients with renal cell carcinoma (RCC) receiving axitinib. The results showed that pre-existing proteinuria and non-RAS inhibitor use were significantly associated with the development of higher-grade proteinuria.

CANCER CHEMOTHERAPY AND PHARMACOLOGY (2022)

Article Pharmacology & Pharmacy

Pharmacist-Urologist Collaborative Management Improves Clinical Outcomes in Patients With Castration-Resistant Prostate Cancer Receiving Enzalutamide

Masaki Hirabatake, Hiroaki Ikesue, Yuna Iwama, Kei Irie, Shintaro Yoshino, Toshinari Yamasaki, Tohru Hashida, Mutsushi Kawakita, Nobuyuki Muroi

Summary: The study investigated the efficacy of a collaborative management program between pharmacists and urologists for CRPC patients receiving enzalutamide, and found that collaborative management was useful for prolonging the time to enzalutamide discontinuation.

FRONTIERS IN PHARMACOLOGY (2022)

Article Nutrition & Dietetics

Association between 25-hydroxyvitamin D levels and COVID-19 severity

Tomoki Takase, Naoko Tsugawa, Takayuki Sugiyama, Hiroaki Ikesue, Masaaki Eto, Tohru Hashida, Keisuke Tomii, Nobuyuki Muroi

Summary: This study demonstrated a significant association between low serum 25(OH)D levels and severe COVID-19 among Japanese patients, suggesting that vitamin D status may be an independent risk factor for severe illness.

CLINICAL NUTRITION ESPEN (2022)

Article Biochemistry & Molecular Biology

Omeprazole Suppresses Oxaliplatin-Induced Peripheral Neuropathy in a Rodent Model and Clinical Database

Keisuke Mine, Takehiro Kawashiri, Mizuki Inoue, Daisuke Kobayashi, Kohei Mori, Shiori Hiromoto, Hibiki Kudamatsu, Mayako Uchida, Nobuaki Egashira, Satoru Koyanagi, Shigehiro Ohdo, Takao Shimazoe

Summary: This study investigates the preventive effect of omeprazole on oxaliplatin-induced peripheral neuropathy.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)

Article Pharmacology & Pharmacy

Pharmacokinetic and pharmacodynamic simulation for the quantitative risk assessment of linezolid-associated thrombocytopenia

Tetsushu Onita, Noriyuki Ishihara, Amika Ikebuchi, Takahisa Yano, Nobuhiro Nishimura, Hiroki Tamaki, Kazuro Ikawa, Norifumi Morikawa, Kohji Naora

Summary: The safety target achievement rate estimated by the PK/PD simulation may represent an important index for risk assessment of LZD-induced thrombocytopenia, and this risk increases with the duration of LZD therapy.

JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS (2022)

Article Pharmacology & Pharmacy

Osteonecrosis of the Jaw Caused by Denosumab in Treatment-Naive and Pre-Treatment with Zoledronic Acid Groups: A Time-to-Onset Study Using the Japanese Adverse Drug Event Report (JADER) Database

Shiori Hasegawa, Hiroaki Ikesue, Riko Satake, Misaki Inoue, Yu Yoshida, Mizuki Tanaka, Kiyoka Matsumoto, Wataru Wakabayashi, Keita Oura, Nobuyuki Muroi, Tohru Hashida, Kazuhiro Iguchi, Mitsuhiro Nakamura

Summary: This study evaluated and compared the time-to-onset profile for medication-related osteonecrosis of the jaw associated with denosumab in treatment-naive and pre-treated patients with zoledronic acid. The results showed a shorter onset time in the post-zoledronic acid group and highlighted the importance of considering the early risk of medication-related osteonecrosis of the jaw when switching patients from zoledronic acid to denosumab treatment.

DRUGS-REAL WORLD OUTCOMES (2022)

Article Pharmacology & Pharmacy

Evaluating the safety and efficiency of robotic dispensing systems

Tomoki Takase, Norio Masumoto, Naoki Shibatani, Yusaku Matsuoka, Fumiaki Tanaka, Masaki Hirabatake, Hiroko Kashiwagi, Itaru Nishioka, Hiroaki Ikesue, Tohru Hashida, Naoshi Koide, Nobuyuki Muroi

Summary: This study evaluated the effect of automated dispensing robots and collaborative work with pharmacy support staff on medication dispensing. The results showed that the introduction of robotic dispensing system significantly reduced the incidence of dispensing errors and the dispensing time of pharmacists. The robotic dispensing system could partially replace the work of pharmacists and enhance the clinical care for patients.

JOURNAL OF PHARMACEUTICAL HEALTH CARE AND SCIENCES (2022)

Article Medical Laboratory Technology

Population Pharmacokinetics of Nivolumab in Japanese Patients with Nonsmall Cell Lung Cancer

Makiko Tohi, Kei Irie, Tomoyuki Mizuno, Hiroyuki Okuyoshi, Masaki Hirabatake, Hiroaki Ikesue, Nobuyuki Muroi, Masaaki Eto, Shoji Fukushima, Keisuke Tomii, Tohru Hashida

Summary: This study aimed to characterize the real-world population pharmacokinetics (PK) of nivolumab in Japanese patients with non-small cell lung cancer (NSCLC). Population PK analysis revealed that clearance of nivolumab was influenced by factors such as serum albumin level, estimated glomerular filtration rate, and treatment period. Further studies are needed to determine optimal dosing regimens for these patients.

THERAPEUTIC DRUG MONITORING (2023)

Article Pharmacology & Pharmacy

Risk Factors of Proteinuria in Patients with Hepatocellular Carcinoma Receiving Lenvatinib

Hiroaki Ikesue, Haruna Yamamoto, Masaki Hirabatake, Tohru Hashida, Hobyung Chung, Tetsuro Inokuma, Nobuyuki Muroi

Summary: Proteinuria is a common adverse event in patients with hepatocellular carcinoma (HCC) receiving lenvatinib treatment. This study retrospectively reviewed the medical records of HCC patients receiving lenvatinib and identified lower baseline estimated glomerular filtration rate (eGFR) as a risk factor for developing proteinuria.

BIOLOGICAL & PHARMACEUTICAL BULLETIN (2022)

Article Pharmacology & Pharmacy

Polypharmacy-associated potential contraindications of drug prescriptions in patients with primary angle closure disease in a real-world setting

Fumiaki Tanaka, Naoki Shibatani, Kazumi Fujita, Hiroaki Ikesue, Satoru Yoshimizu, Nobuyuki Muroi, Yasuo Kurimoto, Tohru Hashida

Summary: In this study, it was found that about 20% of patients with PACD received medications potentially contraindicated for PACD, such as anticholinergics. Attention should be paid to patients prescribed multiple drugs for adverse events, such as increase in intraocular pressure.

JOURNAL OF PHARMACEUTICAL HEALTH CARE AND SCIENCES (2021)

暂无数据